 |
Current Studies
If you think you may be eligible for one of the studies below, please call the Clinical Research Department at (316) 689-9542 or 1-800-876-5111 ext. 9542 for more information.
Endocrinology
Type 2 Diabetes
- Enrollment Criteria: Type 2 Diabetes with a HgA1C of 7.0 to 10.0, a BMI < 45, with a history of cardiovascular disease, peripheral vascular disease or stroke.
- Length of Study: 4 years
- Spaces Available: 6
- Type of Medication for Study: Oral
- Location of Study: Murdock
- Coordinator: Pat
Pulmonary Medicine
Idiopathic Pulmonary Fibrosis (IPF)
- Enrollment Criteria: IPF for less than three years and IPF progression in last year.
- Length of Study: 1 year
- Spaces Available: 3–4
- Type of Medication for Study: IV infusion
- Location of Study: Murdock
- Coordinator: Angela
Rheumatology
Gout
- Enrollment Criteria: Age 18 years and older with a history of cardiovascular disease and gout.
- Length of Study: 5 years
- Spaces Available: Unlimited
- Type of Medication for Study: Oral
- Location of Study: Murdock
- Coordinator: Sheila
Rheumatoid Arthritis
- Enrollment Criteria: Age 18 years and older, male or female with rheumatoid arthritis for more than 6 months.
- Length of Study: 6 months
- Spaces Available: 6
- Type of Medication for Study: IV infusion and subcutaneous injection
- Location of Study: Murdock
- Coordinator: Dorothy
Rheumatoid Arthritis
- Enrollment Criteria: Age 18 years and older with active RA longer than 6 months. Currently on methotrexate and no failure of a biologic.
- Length of Study: 12 months followed by open label extension study
- Spaces Available: 5
- Type of Medication for Study: Oral
- Location of Study: Murdock
- Coordinator: Angela
Rheumatoid Arthritis
- Enrollment Criteria: Ages 18–64 years, male or female on methotrexate for rheumatoid arthritis.
- Length of Study: 6 months
- Spaces Available: 6
- Type of Medication for Study: infusion
- Location of Study: Murdock
- Coordinator: Karen
Rheumatoid Arthritis
- Enrollment Criteria: Ages 18–80 years, male or female may be treatment naive or on DMARD.
- Length of Study: 24 weeks followed by an open label extension
- Spaces Available: 6
- Type of Medication for Study: injection
- Location of Study: Murdock
- Coordinator: Sheila
Urology
Benign Prostate Hypertrophy
- Enrollment Criteria: Age 45 years and older, male, BPH with urinary obstruction.
- Length of Study: 24 weeks
- Spaces Available: 8
- Type of Medication for Study: Oral
- Location of Study: Murdock
- Coordinator: Dorothy
|
|
|
|
Home
Specialties and Services
